Effect of IMOD™ on the inflammatory process after acute ischemic stroke: A randomized clinical trial

DARU, Journal of Pharmaceutical Sciences

Volumn 21, Issue 1, 2013, Pages

  Farhoudi, Mehdi ^a   Najafi Nesheli, Mahdi ^a   Hashemilar, Mazyar ^a   Mahmoodpoor, Ata ^b   Sharifipour, Ehsan ^c   Baradaran, Behzad ^a   Taheraghdam, Aliakbar ^a   Savadi Oskouei, Daryoush ^a   Sadeghi Bazargani, Homayoun ^a   Sadeghi Hokmabadi, Elyar ^c   Akbari, Hosein ^c   Rikhtegar, Reza ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

IMOD ; Inflammatory markers; Ischemic cerebro vascular accident

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMOD; INTERLEUKIN 6; SETARUD; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; INFLAMMATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SERUM; STROKE PATIENT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84876140839     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-21-26     Document Type: Article

References (45)

1. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ, Lancet 2006 367 1747 1757 10.1016/S0140-6736(06)68770-9 16731270 (Pubitemid 43767064)
2. Systemic infection, inflammation and acute ischemic stroke. McColl BW, Allan SM, Rothwell NJ, Neuroscience 2009 158 1049 1061 10.1016/j.neuroscience. 2008.08.019 18789376
3. The inflammatory response in stroke. Wang Q, Tang XN, Yenari MA, J Neuroimmunol 2007 184 53 68 10.1016/j.jneuroim.2006.11.014 17188755 (Pubitemid 46365991)
4. Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. Sairanen T, Carpen O, Karjalainen-Lindsberg ML, Paetau A, Turpeinen U, Kaste M, Lindsberg PJ, Stroke 2001 32 1750 1758 10.1161/01.STR.32.8.1750 11486101
5. The role of cytokines in the neuropathology of stroke and neurotrauma. Feuerstein GZ, Wang X, Barone FC, Neuroimmunomodulation 1998 5 143 159 10.1159/000026331 9730680 (Pubitemid 28417026)
6. Inflammation and glial responses in ischemic brain lesions. Stoll G, Jander S, Schroeter M, ProgNeurobiol 1998 56 149 171 (Pubitemid 28432563)
7. Inflammation as Therapeutic Objective in Stroke. Jordán J, Segura T, Brea D, Galindo MF, Castillo J, Current Pharm Design 2008 14 3549 3564 10.2174/138161208786848766
8. Studies on potential mutagenic and genotoxic activity of Setarud. Khorram Khorshid HR, Novitsky YA, Abdollahi M, Shahhosseiny MH, Sadeghi B, Madani H, Rahimi R, Farzamfar B, DARU 2008 16 223 228
9. Preclinical and phase 1 clinical safety of Setarud (IMOD™), a novel immunomodulator. Khairandish P, Mohraz M, Farzamfar B, Abdollahi M, Shahhosseiny MH, Madani H, Sadeghi B, Heshmat R, Gharibdust F, Khorram-Khorshid HR, DARU 2009 17 148 156
10. Safety and efficacy of Setarud (IMOD TM) among people living with HIV/AIDS: a review. Paydary K, Emamzadeh-Fard S, Khorram Khorshid HR, Kamali K, SeyedAlinaghi S, Mohraz M, Recent Pat Antiinfect Drug Discov 2012 7 1 66 72 10.2174/157489112799829756 22353002
11. Examination of Setarud (IMOD™) in the management of patients with severe sepsis. Mahmoodpoor A, Eslami K, Mojtahedzadeh M, Najafi A, Ahmadi A, Dehnadi-Moghadam A, Mohammadirad A, Baeeri M, Abdollahi M, DARU 2010 18 23 28 22615589
12. Efficacy of Setarud (IMod), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab. Baghaei A, Esmaily H, Abdolghaffari AH, Baeeri M, Gharibdoost F, Abdollahi M, Indian J Biochem Biophys 2010 47 4 219 226 21174949
13. Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study. Look MP, Rockstroh JK, Rao GS, Barton S, Lemoch H, Kaiser R, Kupfer B, Sudhop T, Spengler U, Sauerbruch T, Eur J Clin Invest 1998 28 389 397 10.1046/j.1365-2362.1998. 00301.x 9650013 (Pubitemid 28261223)
14. EgbewaleBE, Adewole TA. Plasma selenium concentration and glutathione peroxidase activity in HIV-1/AIDS infected patients: a correlation with the disease progression. Ogunro PS, Ogungbamigbe TO, Elemie PO, Niger Postgrad Med J 2006 13 1 5 16633369
15. Efficacy of Setarud (IMOD™), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes. Mohseni-Salehi-Monfared SS, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M, Arch Med Sci. 2010 6 5 663 669 doi: 10.5114/aoms.2010.17078. Epub 2010 Oct 26 22419922
16. In vitro immunoinhibitory effects of Setarud on human B lymphocyte. Shirazi FG, Raoufi A, Yousefi M, Asgarian-Omran H, Memarian A, Khoshnoodi J, Younesi V, Shokri F, J Medicinal Plants Research 2011 5 11 2223 2231
17. Anti-inflammatory effects of South American Tanacetumvulgare. Schinella GR, Giner RM, Mordujovich BP, Rhos JL, J Pharm Pharmacol 1998 50 1069 1074 10.1111/j.2042-7158.1998.tb06924.x 9811170 (Pubitemid 28464095)
18. Some medicinal plants as immunostimulant for fish. Karata SD, Arda N, Candan A, J Ethnopharmacol 2003 88 1 99 106 10.1016/S0378-8741(03)00182-X 12902058 (Pubitemid 36945356)
19. Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function. Abdollahi M, Rahmat-Jirdeh N, Soltaninejad K, Hum ExpToxicol 2001 20 28 33 10.1191/096032701667736070 (Pubitemid 32372414)
20. The importance of selenium to human health. Rayman MP, Lancet 2000 356 233 241 10.1016/S0140-6736(00)02490-9 10963212 (Pubitemid 30446984)
21. TheTOAST Investigators. Classification of subtypes of acute ischemic stroke. Adams HP, Bendixen BH, Kappelle J, Biller J, Love B, Gordon MD, Marsh EE, Stroke 1993 24 35 41 10.1161/01.STR.24.1.35 7678184 (Pubitemid 23014379)
22. Systemic inflammatory challenges compromise survival after experimental stroke via augmenting brain inflammation, blood- brain barrier damage and brain oedema independently of infarct size. Dénes A, Ferenczi S, Kovács KJ, J Neuroinflammation 2011 8 164 10.1186/1742-2094-8-164 22114895
23. Brain-immune interactions and ischemic stroke: clinical implications. Kamel H, Iadecola C, Arch Neurol 2012 69 576 581 10.1001/archneurol.2011.3590 22782509
24. Inflammatory and neuroimmunomodulatory Changes in Acute Cerebral Ischemia. Brea D, Sobrino T, Ramos-Cabrer P, Castillo J, Cerebrovasc Dis 2009 27 48 64 19372660
25. Neuroprotection by inhibiting the c-Jun N-terminal kinase pathway after cerebral ischemia occurs independently of interleukin-6 and keratinocyte-derived chemokine (KC/CXCL1) secretion. Benakis C, Vaslin A, Pasquali C, Hirt L, J Neuroinflammation 2012 9 76 10.1186/1742-2094-9-76 22533966
26. Anti-inflammatory modulators in stroke. O'Neill MJ, Astles PC, Allan SM, Anthony DC, Drug disc today 2004 1 59 67 10.1016/j.ddmec.2004.08.011 (Pubitemid 41128992)
27. Identification of enhanced cytokine generation following sepsis. Dream of magic bullet for mortality prediction and therapeutic evaluation. Hamishehkar H, Beigmohammadi MT, Abdollahi M, Ahmadi A, Mahmoodpour A, Mirjalili MR, Abrishami R, Khoshayand MR, Eslami K, Kanani M, DARU 2010 18 155 162 22615611
28. Effect of N-Acetyl cysteine on microalbuminuria in patients with acute respiratory distress syndrome. Najafi A, Mojtahedzadeh M, Mahmoodpoor A, Aghamohammadi M, Ahmadi A, Nahreini S, Pazuki M, Khajavi MR, Abdollahi M, Arc Med Sci 2009 3 1 7
29. Inflammatory cytokines in experimental and human stroke. Lambertsen KL, Biber K, Finsen B, J Cereb Blood Flow Metab 2012 32 1677 1698 10.1038/jcbfm.2012.88 22739623
30. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. Pradillo JM, Denes A, Greenhalgh AD, Boutin H, Drake C, McColl BW, Barton E, Proctor SD, Russell JC, Rothwell NJ, Allan SM, J Cereb Blood Flow 2012 39 1810 1819
31. Identification of a key pathway required for the sterile inflammatoryresponse triggered by dying cells. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL, Naturemedicine 2007 13 851 856 (Pubitemid 47038190)
32. Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Denes A, Pinteaux E, Rothwell NJ, Allan SM, Cerebrovasc Dis 2011 32 517 527 10.1159/000332205 22104408
33. Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. Shin JA, Lee H, Lim YK, Koh Y, Choi JH, Park EM, J Neuroimmunol 2010 227 93 100 10.1016/j.jneuroim.2010.06.017 20655115
34. Effect of flogensim in the treatment of postischemic inflammation (according to results of using interleukin-6 in patients with acute brain infarction). Vinychuk SM, Cheren'ko TM, LikSprava 2007 3 80 84
35. Early enteral nutrition with whey protein or casein in elderly patients with acute ischemic stroke: a double-blind randomized trial. De Aguilar-Nascimento JE, Prado Silveira BR, Dock-Nascimento DB, Nutrition 2011 27 440 444 10.1016/j.nut.2010.02.013 21167685
36. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Montaner J, Chacón P, Krupinski J, Rubio F, Millán M, Molina CA, Hereu P, Quintana M, Alvarez SJ, Eur J Neurol 2008 15 82 90 18070096 (Pubitemid 350265291)
37. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW, J ThrombThrombolysis 2012 33 88 94 10.1007/s11239-011-0637-y
38. Positive effect of septimeb on mortality rate in severe sepsis: a novel non antibiotic strategy. Eslami K, Mahmoodpoor A, Ahmadi A, Abdollahi M, Kamali K, Mousavi S, Najafi A, Baeeri M, Hamishehkar H, Kouti L, DARU 2012 20 40 23351964
39. Novitsky YA, Madani H, Gharibdoust F, Farhadi M, Farzamfar B, Mohraz M, Use of a combination of ethanolic Rosa sp., Urtica Dioica and Tanacetum Vulgare extracts, further comprising selenium and urea and having been exposed to a pulsed electromagnetic field, for the preparation of a medicament for immunostimulation and/or treatment of HIV infections. USPTO Patent Application 20090208598; EU Patent Application 087825: International Application PCT/EP2006/000820 2007 http://www.google.com/patents/US20090208598
40. Neuroprotective effects of the immunomodulatory drug Setarud on cerebral ischemia in male rats. Vafaee F, Zangiabadi N, Pour FM, Dehghanian F, Asadi-Shekaari M, Afshar HK, Neural Regen Res 2012 7 27 2085 2091
41. Inflammation in Ischemic Stroke Subtypes. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G, Curr Pharm Des 2012 29 [Epub ahead of print]
42. C-reactive Protein and Early Mortality in Acute Ischemic Stroke. Dewan KR, Rana PV, Kathmandu Univ Med J 2011 9 252 5
43. Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P, Br J ClinPharmacol. 2012 74 230 40
44. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study. Idicula TT, Brogger J, Naess H, Waje-Andreassen U, Thomassen L, BMC Neurol 2009 9 18 10.1186/1471-2377-9-18 19400931
45. C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: correlation with clinical outcome. Rajeshwar K, Kaul S, Al-Hazzani A, Babu MS, Balakrishna N, Sharma V, Jyothy A, Munshi A, Inflammation 2012 35 3 978 84 10.1007/s10753-011-9401-x 22038116